Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Rite Aid To Gain Specialty Drug, Part D Platforms With PBM EnvisionRx

This article was originally published in The Pink Sheet Daily

Executive Summary

The drug store chain will purchase EnvisionRx, which serves over 21 million members and expects to manage 145 million pharmacy claims in 2015, for $2 billion in cash and stock.

You may also be interested in...

Deal Watch: Teva Boosts CNS Portfolio With $3.2 Billion Purchase Of Auspex

Novartis raises its game in immuno-oncology through Aduro collaboration, while Merck Serono partners up with a CAR-T program at Intrexon. UnitedHealth grows its PBM business by acquiring Catamaran; Horizon expands its orphan drug portfolio in buyout of Hyperion.

OptumRx To Be ‘Competitive Force’ In PBM Industry With Catamaran Buy

The merger of UnitedHealth Group’s pharmacy benefit manager OptumRx with Catamaran could give the combined firm greater pricing leverage as it becomes one of the industry's giants, along with CVS Health’s Caremark and Express Scripts.

Express Scripts-Medco Merger Closes With No Divestitures Needed

The FTC voted in a split 3-1 vote to close its investigation and allow Express Scripts’ $29.1 billion acquisition of rival PBM Medco to proceed.

Related Content


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts